ANGLE plc, a liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, has announced that it has entered a collaboration with Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company.

Under the terms of the agreement, blood samples from cancer patients will be processed by ANGLE's research and development team utilising the Parsortix system for the capture and harvest of intact cancer cells for downstream molecular analysis. Results for this analysis will compare CTC-DNA with matched patient tissue samples using Myriad Genetics' existing tissue-based assay.

ANGLE Chief Executive, Andrew Newland, commented, “We are delighted to be working with Myriad Genetics, a major player in tissue-based companion diagnostic tests, seeking to extend their tests to work on a simple blood test using CTCs harvested by the Parsortix system. We look forward to working with Myriad Genetics to progress this collaboration, which has the potential to have a substantial impact on patient treatment by improving access to actionable genomic data.”